FR2613934B1 - Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament - Google Patents

Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament

Info

Publication number
FR2613934B1
FR2613934B1 FR8716489A FR8716489A FR2613934B1 FR 2613934 B1 FR2613934 B1 FR 2613934B1 FR 8716489 A FR8716489 A FR 8716489A FR 8716489 A FR8716489 A FR 8716489A FR 2613934 B1 FR2613934 B1 FR 2613934B1
Authority
FR
France
Prior art keywords
sub
methyl
sup
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8716489A
Other languages
English (en)
French (fr)
Other versions
FR2613934A1 (fr
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2613934(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of FR2613934A1 publication Critical patent/FR2613934A1/fr
Application granted granted Critical
Publication of FR2613934B1 publication Critical patent/FR2613934B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
FR8716489A 1985-06-25 1987-11-27 Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament Expired - Fee Related FR2613934B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
FR2613934A1 FR2613934A1 (fr) 1988-10-21
FR2613934B1 true FR2613934B1 (fr) 1993-07-09

Family

ID=40347948

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8716489A Expired - Fee Related FR2613934B1 (fr) 1985-06-25 1987-11-27 Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament

Country Status (22)

Country Link
US (2) US4753789A (es)
EP (2) EP0431443A3 (es)
JP (2) JPS6253920A (es)
AT (2) ATE134510T1 (es)
AU (2) AU609028B2 (es)
BE (1) BE1002249A4 (es)
CA (1) CA1296637C (es)
CH (1) CH672068A5 (es)
CY (1) CY2000A (es)
DE (2) DE3650488T2 (es)
DK (1) DK624687A (es)
FR (1) FR2613934B1 (es)
GB (3) GB8516083D0 (es)
HK (1) HK82597A (es)
IE (1) IE60908B1 (es)
IL (1) IL84638A (es)
IT (1) IT1211937B (es)
NL (1) NL8702853A (es)
NZ (1) NZ222743A (es)
SE (1) SE8704747L (es)
SG (1) SG43311A1 (es)
ZA (1) ZA878927B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US4845115A (en) * 1986-12-17 1989-07-04 Glaxo Group Limited Method of medical treatment
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
JPH0754759B2 (ja) * 1987-04-27 1995-06-07 日本電信電話株式会社 プラズマ処理方法および装置並びにプラズマ処理装置用モード変換器
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
JPH06509073A (ja) * 1991-06-26 1994-10-13 セプラコア，インコーポレーテッド 光学的に純粋なｓ（−）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
EP0591434A4 (en) * 1991-06-26 1994-09-14 Sepracor Inc Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
CA2157671A1 (en) * 1993-03-08 1994-09-15 Kiyotaka Katsuta Medicament for treating or preventing cerebrovascular diseases
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
CA2505990C (en) * 2002-11-15 2009-05-19 Helsinn Healthcare S.A. Palonosetron for the treatment of chemotherapy-induced emesis
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
TWI355936B (en) 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
WO2005108392A2 (en) * 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
JP2010050046A (ja) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp プラズマ処理装置
AU2010343147A1 (en) 2009-12-28 2012-07-19 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
US20200054611A1 (en) 2017-01-09 2020-02-20 Gt Biopharma, Inc. Use and composition for treating myasthenia gravis and other myasthenic syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (en) * 1980-05-17 1981-11-25 FISONS plc Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
HU193592B (en) * 1984-01-25 1987-11-30 Glaxo Group Ltd Process for producing tetrahydro-carbazolone derivatives
EP0191562B1 (en) * 1985-01-23 1991-07-10 Glaxo Group Limited Tetrahydrocarbazolone derivatives
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
GB2200046A (en) 1988-07-27
AU616386B2 (en) 1991-10-31
CY2000A (en) 1997-12-05
JPH0324447B2 (es) 1991-04-03
DE3740351A1 (de) 1988-06-09
AU8191487A (en) 1988-06-02
GB2200046B (en) 1990-09-26
SE8704747D0 (sv) 1987-11-27
US4929632A (en) 1990-05-29
NL8702853A (nl) 1988-06-16
EP0226266B1 (en) 1996-02-28
US4753789A (en) 1988-06-28
GB8727836D0 (en) 1987-12-31
HK82597A (en) 1997-06-27
BE1002249A4 (fr) 1990-11-06
SG43311A1 (en) 1997-10-17
EP0431443A3 (en) 1991-09-18
IT8748643A0 (it) 1987-11-27
DK624687A (da) 1988-05-29
AT395374B (de) 1992-12-10
EP0431443A2 (en) 1991-06-12
ATA312587A (de) 1992-05-15
CH672068A5 (es) 1989-10-31
IT1211937B (it) 1989-11-08
GB8628474D0 (en) 1987-01-07
DE3650488T2 (de) 1996-09-05
AU6703786A (en) 1988-06-30
JPS63198623A (ja) 1988-08-17
EP0226266A2 (en) 1987-06-24
IE60908B1 (en) 1994-08-24
FR2613934A1 (fr) 1988-10-21
NZ222743A (en) 1991-09-25
ATE134510T1 (de) 1996-03-15
IE873230L (en) 1988-05-28
DK624687D0 (da) 1987-11-27
DE3650488D1 (de) 1996-04-04
GB8516083D0 (en) 1985-07-31
SE8704747L (sv) 1988-05-29
CA1296637C (en) 1992-03-03
ZA878927B (en) 1988-10-26
AU609028B2 (en) 1991-04-26
EP0226266A3 (en) 1990-01-24
JPS6253920A (ja) 1987-03-09
IL84638A (en) 1992-05-25

Similar Documents

Publication Publication Date Title
FR2613934B1 (fr) Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament
ES530242A0 (es) Un procedimiento para preparar sales de un derivado de imidazol
ES8105292A1 (es) Procedimiento para la obtencion de derivado de la difenilu- rea halogenosustituidos
FI872864A (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
CA2029599A1 (en) Medicaments containing as active substance sulphur-containing carboxylic acids and their use in combating retroviruses
NO932634L (no) Polyvinylaminderivater med hydrofile sentere, fremgangsmaate for fremstilling av dem saavel som anvendelsen av forbindelsene som legemiddel, virkestoffbaerere og naeringsmiddel-hjelpestoff
CA2009593A1 (en) Medicament containing dihydrolipoic acid as active substance
ES8506615A1 (es) Un procedimiento para la preparacion de carboxamidas
GB8826595D0 (en) Active compounds
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ATE2265T1 (de) Sekundaere amine, ihre herstellung und verwendung in pharmazeutischen zusammensetzungen.
KR880007074A (ko) 의약품
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
IL70797A0 (en) Triazole derivatives,their preparation and pharmaceutical and agricultural compositions containing them
US4439450A (en) Treatment of the blood-brain barrier with ibuprofen
MX9705737A (es) Indanilidinacetilguanidinas sustituidas, procedimiento para su preparacion, su uso como medicamentos o agentes de diagnostico y medicamentos que las contienen.
KR920006277A (ko) 칼슘 흡수 억제제
DK644487D0 (da) Farmaceutisk praeparat indeholdende en 2-oxo-imidazolidinforbindelse
ES8504816A1 (es) Un procedimiento de preparacion de un derivado de cefalosporina
ES8201152A1 (es) Procedimiento para la preparacion de acidos 5-sulfamoilorta-nilicos
KR880005931A (ko) 제약 조성물
KR890003678A (ko) 부정맥 치료제

Legal Events

Date Code Title Description
ST Notification of lapse